Company Challenge
When Archimed, a leading global healthcare private equity firm, acquired Ametris (formerly ActiGraph) in 2020, the company was well-positioned to enter a new phase of growth.
For nearly two decades, Ametris' FDA-cleared wearable monitors and robust analytics platform had been widely used to quantify human movement in academic and population health research. Its differentiated solutions were increasingly being adopted by top-tier global pharmaceutical and life sciences organizations to capture objective patient outcomes in clinical trials.
To achieve the next level of growth, Ametris needed to professionalize, evolving from a founder-led technology organization into a market-leading business. This shift required experienced executives who could establish robust financial and commercial infrastructure, processes, systems, and controls, while building the technology, leadership, and product strategy required to scale.
At the same time, the President & Chief Operating Officer was promoted into his first CEO role. Given this move, the company's future success would require an exceptionally strong leadership team. Ametris sought an executive search partner with deep expertise in PE-backed healthcare technology. They turned to JM Search.
Solution & Results
The partnership between JM Search and Ametris initially focused on building the company's financial and commercial functions. JM Search was selected to source both the company's Chief Financial Officer and Chief Commercial Officer. For these critical roles, JM Search identified executives with the experience and expertise to build teams and processes, strengthen financial planning and reporting, develop scalable sales and pricing structures, and deepen strategic customer relationships to capitalize on growing demand and accelerate global expansion.
The following year, Ametris worked with JM Search to add its first-ever Chief Technology Officer. In 2022, Ametris leveled up both their commercial and finance functions, further scaling the go-to-market organization and bringing in a CFO with deep experience growing and exiting PE-backed organizations. Under the leadership of these two executives, the company continued to grow rapidly.
In 2025, Ametris acquired the life sciences division of Biofourmis, expanding its product portfolio with AI-driven digital trial technology. With the increasing sophistication of the business, Ametris sought a Chief Product Officer to unify product strategy and build an innovation roadmap aligned with customer needs, market opportunity, and business value. They partnered with JM Search to find the right leader for the role.
This expanded executive team helped Ametris more than double its revenue within five years, cementing its position in the digital clinical trial market.
In 2026, Ametris was acquired by Signant Health, a global clinical trial technology and evidence generation company that helps pharmaceutical and contract research organizations streamline and digitize clinical research. The acquisition brings together complementary digital measurement and clinical trial technologies to deliver more comprehensive patient insights through a unified platform to advance the development of new therapies. The CFO, CTO, and Chief Product Officer placed by JM Search were critical members of the leadership team that delivered this successful outcome.
